Protalix BioTherapeutics to Announce First Quarter 2026 Financial Results and Business Update on May 13, 2026 Protalix BioTherapeutics to Announce First Quarter 2026 Financial Results and Business...
Protalix BioTherapeutics to Announce First Quarter 2026 Financial Results and Business Update on May 13, 2026 Protalix BioTherapeutics to Announce First Quarter 2026 Financial Results and Business...
Protalix BioTherapeutics Reports Fiscal Year 2025 Financial and Business Results Protalix BioTherapeutics Reports Fiscal Year 2025 Financial and Business Results PR Newswire CARMIEL, Israel, March...
Protalix BioTherapeutics to Announce Fiscal Year 2025 Financial Results and Business Update on March 18, 2026 Protalix BioTherapeutics to Announce Fiscal Year 2025 Financial Results and Business...
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Protalix BioTherapeutics, Inc. (Protalix or the Company) (NYSE...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Protalix BioTherapeutics, Inc. - PLX INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of...
However, Protalix CEO said that the results of the review do not change the priority of the company to reduce treatment burden for patients with Fabry disease.
Regulus Therapeutics shares surged after Novartis announced a $1.7 billion acquisition, but analysts downgraded the stock citing limited upside. Retail sentiment remained bullish, with speculation of a higher bid or FDA-driven gains.